Schizophrenia — Deal Benchmarks & Valuation
Market Analysis
Schizophrenia is one of the most actively transacted indications in neurology licensing. Phase 2 deals for schizophrenia carry a median total deal value of $2.9B, with upfront payments ranging from $161M to $490M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for schizophrenia deals allocate $840M to development milestones, $917M to regulatory milestones, and $789M to commercial milestones. Royalty rates range from 12.1% to 19.4% at the base tier, with tiered escalation reaching 16.1%-23.4% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for schizophrenia licensing?
What royalty rates are standard for schizophrenia deals?
How are schizophrenia deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.